S411 48 savaysa package insert 2015 daiichi sankyo

S4.1.1-48. Savaysa [package insert] 2015. Daiichi Sankyo, Inc; Parsippany, NJ.
S4.1.1-49. Nielsen PB, Skjøth F, Overvad TF, et al. Female sex is a risk modifier
rather than a risk factor for stroke in atrial fibrillation: should we
use a CHA2DS2-VA score rather than CHA2DS2-VASc? Circulation.
2018;137:832–40.
S4.1.1-50. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for
atrial fibrillation: antithrombotic therapy and prevention of throm-
bosis, 9th ed: American College of Chest Physicians evidence-based
clinical practice guidelines. Chest. 2012;141:e531S–75.
S4.1.1-51. US Renal Data System. 2016 USRDS annual data report: epidemiol-
ogy of kidney disease in the United States. Bethesda, MD. National
Institutes of Health, National Institute of Diabetes and Digestive and
Kidney Diseases; 2016.
S4.1.1-52. Sood MM, Komenda P, Sood AR, et al. The intersection of risk and
benefit: is warfarin anticoagulation suitable for atrial fibrillation in
patients on hemodialysis? Chest. 2009;136:1128–33.
S4.1.1-53. Nochaiwong S, Ruengorn C, Awiphan R, et al. Efficacy and safety
of warfarin in dialysis patients with atrial fibrillation: a systematic
review and meta-analysis. Open Heart. 2016;3:e000441.
S4.1.1-54. Deal EN, Pope H, Ross W. Apixaban use among patients with severe
renal impairment. Ann Pharmacother. 2014;48:1667.
S4.1.1-55. Stanton BE, Barasch NS, Tellor KB. Comparison of the safety and
effectiveness of apixaban versus warfarin in patients with severe
renal impairment. Pharmacotherapy. 2017;37:412–9.
S4.1.1-56. Mavrakanas TA, Samer CF, Nessim SJ, et al. Apixaban pharmacoki-
netics at steady state in hemodialysis patients. J Am Soc Nephrol.
2017;28:2241–8.
S4.1.1-57. Reed D, Palkimas S, Hockman R, et al. Safety and effectiveness
of apixaban compared to warfarin in dialysis patients. Res Pract
Thromb Haemost. 2018;2:291–8.
S4.1.1-58. Fauchier L, Clementy N, Bisson A, et al. Should atrial fibrillation
patients with only 1 nongender-related CHA2DS2-VASc risk factor
be anticoagulated? Stroke. 2016;47:1831–6.
S4.1.1-59. Dias C, Moore KT, Murphy J, et al. Pharmacokinetics, pharmacody-
namics, and safety of single-dose rivaroxaban in chronic hemodialy-
sis. Am J Nephrol. 2016;43:229–36.
Downloaded from by on March 4, 2020

January et al 2019 Focused Update on Atrial Fibrillation
Circulation. 2019;140:e125–e151. DOI: 10.1161/CIR.0000000000000665 July 9, 2019
e145
CLINICAL STATEMENTS
AND GUIDELINES
S4.1.1-60. De Vriese AS, Caluwé R, Bailleul E, et al. Dose-finding study of riva-
roxaban in hemodialysis patients. Am J Kidney Dis. 2015;66:91–8.
S4.1.1-61. Chan KE, Edelman ER, Wenger JB, et al. Dabigatran and rivaroxa-
ban use in atrial fibrillation patients on hemodialysis. Circulation.
2015;131:972–9.
S4.1.1-62. Van de Werf F, Brueckmann M, Connolly SJ, et al. A comparison
of dabigatran etexilate with warfarin in patients with mechani-
cal heart valves: the randomized, phase II study to evaluate
the safety and pharmacokinetics of oral dabigatran etexilate in
patients after heart valve replacement (RE-ALIGN). Am Heart J.